STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology
drugs-4

Eli Lilly’s GLP-1 Drugs Outshine Novo Nordisk’s in Weight Loss: A New Study Confirms

byLiliana Vida
July 10, 2024
in Biotechnology, Large-Cap
Reading Time: 3 mins read
Share on TwitterShare on LinkedIn

Independent research underscores the superior weight loss efficacy of Eli Lilly’s Mounjaro over Novo Nordisk’s Ozempic, stirring debate and market reactions

A recent study conducted by researchers in Washington and Oregon, published by JAMA, has reignited the competition between pharmaceutical giants Eli Lilly and Novo Nordisk over the efficacy of their GLP-1 drugs for weight loss. The findings indicate that Eli Lilly’s Mounjaro significantly outperforms Novo Nordisk’s Ozempic in promoting weight loss among patients.

Study Findings: A Comparative Advantage for Mounjaro

The year-long study revealed that patients treated with Novo Nordisk’s Ozempic experienced an 8% reduction in body weight, whereas those on Eli Lilly’s Mounjaro saw a remarkable 15% reduction. Furthermore, Mounjaro sustained a continuous weight loss trajectory over the year, unlike Ozempic, which showed diminished effectiveness over time. Specifically, 42% of Mounjaro patients lost 15% or more of their body weight, compared to only 18% of Ozempic patients.

Market Reactions and Corporate Responses

In response to the study, Novo Nordisk’s stock dipped over 2% on Tuesday. Novo Nordisk contended that the comparison was not entirely equitable, highlighting several deficiencies in the study’s methodology. According to a spokesperson’s statement to Yahoo Finance, the ideal comparative analysis would involve a head-to-head randomized clinical trial (RCT) focused explicitly on obesity, a scenario yet to be fully realized between tirzepatide (Mounjaro) and semaglutide (Ozempic).

Eli Lilly, while refraining from commenting directly on the study, emphasized its anticipation for the results of its ongoing SURMOUNT-5 head-to-head trial, expected to conclude later this year. This trial aims to provide a more direct comparison between the two drugs.

Implications for Advertising and Market Positioning

The study’s outcomes corroborate initial impressions from the Phase 3 trials of both companies, where Lilly’s tirzepatide demonstrated superior weight loss results compared to Novo’s semaglutide. Leveraging these findings, Eli Lilly has positioned Mounjaro in its advertising as delivering “unmatched weight reduction across all 3 doses vs Ozempic.”

Study Methodology and Limitations

Researchers utilized data from Truveta, ensuring patient anonymity, to analyze a cohort initially comprising 44,000 patients, narrowed down to over 9,000 with similar characteristics. The study included both obese and diabetic patients. Dr. F. Perry Wilson from Yale University noted potential biases, such as a healthier, wealthier, and more educated patient profile for those on Mounjaro.

Novo Nordisk criticized the study for omitting crucial variables such as insurance type, socioeconomic status, baseline BMI, and other factors that could influence weight loss outcomes. The researchers, however, defended their approach, focusing on complete and gender-specific patient information while excluding incomplete data sets.

The Financial Impact of GLP-1s

The market for GLP-1 drugs has surged, translating into billions of dollars in additional revenue for both Eli Lilly and Novo Nordisk. Wall Street projects these once-weekly injectables to contribute between $13 billion and $25 billion to the companies’ revenues this year alone, underscoring the high stakes in this pharmaceutical rivalry.

In conclusion, while Eli Lilly’s Mounjaro appears to hold a competitive edge over Novo Nordisk’s Ozempic in weight loss efficacy, the ongoing debate and future head-to-head trials will be crucial in shaping the market dynamics and patient choices in the GLP-1 drug landscape.

You might like this article:Promising Results for HyBryte in Extended Treatment of Early-Stage CTCL

Tags: biotechBreakingGrowthMoversNewsStock Marketweight loss
Previous Post

Promising Results for HyBryte in Extended Treatment of Early-Stage CTCL

Next Post

Discover Hidden Gems: 5 Undervalued Stocks You Should Look Into

Related Posts

scientist

Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240

byLuca Blaumann
October 29, 2025
0

Achievement validates CAPTN-3 platform scalability and advances IM1240 toward first-in-human clinical trials in 2026 Purple Biotech (PPBT), a clinical-stage biotechnology...

investing

Qualcomm Enters the AI Data Center Battle with Powerful New AI200 and AI250 Chips

byLiliana Vida
October 27, 2025
0

Chipmaker aims to challenge Nvidia and AMD with energy-efficient AI servers and next-generation accelerators launching in 2026 Qualcomm (NASDAQ: QCOM)...

Co-Diagnostics Expands Global Reach with New Saudi Joint Venture

byLuca Blaumann
October 27, 2025
0

CoMira Diagnostics to Localize PCR Manufacturing and Healthcare Innovation Across KSA and 18 MENA Countries Co-Diagnostics (CODX), a leading molecular...

Next Post
investing

Discover Hidden Gems: 5 Undervalued Stocks You Should Look Into

Latest News

Alphabet Tops $100 Billion Quarter as AI Cloud Deals Power Record Growth

Microsoft Reports Strong Q3 Results Driven by Cloud and AI Momentum

Meta Beats on Revenue, Misses EPS as One-Time Tax Charge Weighs on Q3

Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240

Orion Group Holdings Delivers Strong Q3 Results and Raises 2025 Guidance

Based on Your Interest

nvidia-chip
Artificial Intelligence

Nvidia Partners with U.S. Department of Energy to Build Seven AI Supercomputers

October 28, 2025
investing
Artificial Intelligence

Qualcomm Enters the AI Data Center Battle with Powerful New AI200 and AI250 Chips

October 27, 2025
Biotechnology

Co-Diagnostics Expands Global Reach with New Saudi Joint Venture

October 27, 2025

Recommended

Artificial Intelligence

Datavault AI and Wellgistics Partner to Revolutionize Prescription Tracking with Blockchain Technology

October 24, 2025
Large-Cap

AMD Shares Surge as IBM Taps Its Chips for Quantum Computing Breakthrough

October 24, 2025
Large-Cap

Intel Surges After Strong Q3 Earnings Beat, But Manufacturing Challenges Remain

October 23, 2025
Auto Manufacturers

Ford Beats Q3 Estimates but Cuts 2025 Outlook Following Supplier Fire

October 23, 2025
Biotechnology

Scienture Launches Commercial Sales of Arbli™, the First FDA-Approved Ready-to-Use Losartan Suspension

October 23, 2025
Stoxpo

Follow us on social media:

Highlights

  • Alphabet Tops $100 Billion Quarter as AI Cloud Deals Power Record Growth
  • Microsoft Reports Strong Q3 Results Driven by Cloud and AI Momentum
  • Meta Beats on Revenue, Misses EPS as One-Time Tax Charge Weighs on Q3
  • Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240
  • Orion Group Holdings Delivers Strong Q3 Results and Raises 2025 Guidance

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Alphabet Tops $100 Billion Quarter as AI Cloud Deals Power Record Growth

October 29, 2025

Microsoft Reports Strong Q3 Results Driven by Cloud and AI Momentum

October 29, 2025
investing

Meta Beats on Revenue, Misses EPS as One-Time Tax Charge Weighs on Q3

October 29, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.